- Aurora Cannabis completes a $3 million upgrade to its Pemberton, BC facility, now called Aurora Alpine.
- The facility improvements have doubled yield and potency, achieving record levels of 33.7% potency.
- GACP certification enables the facility to export premium medical cannabis internationally.
Aurora Cannabis Inc. (ACB, Financial) has successfully completed a $3 million investment in its manufacturing facility located in Pemberton, British Columbia. The facility, now renamed Aurora Alpine, has undergone significant upgrades over multiple years, resulting in enhanced operational efficiency and increased production capabilities.
Key achievements at the Aurora Alpine facility include a remarkable doubling of yield and potency, with the latter reaching an unprecedented 33.7%. These improvements have been made possible through the integration of Aurora’s proprietary genetics alongside advanced engineering technologies, setting new standards in cultivation precision.
The facility, originally licensed in 2019 under the name Whistler Medical Marijuana Company, now boasts GACP certification. This certification is a strategic advantage for Aurora, allowing the company to expand its presence in global markets through the export of premium medical cannabis products. The renaming to Aurora Alpine underscores the site’s strategic location overlooking Mount Currie in the Pemberton Valley, aligning with the company’s commitment to excellence in cannabis production.
These enhancements not only strengthen Aurora’s position as a leader in the medical cannabis industry but also align with its broader strategy of focusing on high-margin international markets. This strategic focus on operational excellence and targeted investment demonstrates Aurora’s shift towards sustainable profitability within the competitive cannabis sector.
